Novartis trumps Bristol-Myers Squibb at NICE for chronic CML
This article was originally published in Scrip
Novartis looks set to dominate the treatment of chronic phase chronic myeloid leukaemia in England and Wales. NICE, the health technology appraisal body, has said a final draft yes to standard dose Glivec (imatinib) and Glivec follow-on, Tasigna (nilotinib), for the first-line treatment of adults with chronic phase Philadelphia-chromosome positive CML. Bristol-Myers Squibb’s Sprycel (dasatinib) has again lost out on a recommendation on grounds of cost.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.